Navigation Links
Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
Date:3/5/2008

ese forward-looking statements include, but are not limited to, the timing and progress of clinical studies relating to the company's transcatheter valve technologies and the market opportunity for transcatheter technologies. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2007.

Edwards, Edwards SAPIEN and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Ascendra, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Edwards Lifesciences Announces Organizational Changes
2. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
4. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
5. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
6. Edwards Lifesciences Forecasts Strong Growth in 2008
7. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
8. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
9. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
10. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
11. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Florida (PRWEB) , ... September 02, 2015 , ... ... been treated and managed with the use of special anti-vascular endothelial growth factor ... in many more patients, currently does not have a scientific protocol for the ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biomarkers ... offering. This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3
... - AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: ... and oncology, today reported the completion of patient,recruitment ... Phase 3 program,in benign prostatic hyperplasia (BPH), a ... candidate, cetrorelix. The study,involves approximately 600 patients primarily ...
... FRESNO, Calif., April 15 Chairman & CEO, Paul ... agribusiness company, Dr.,Mark E. Whitacre has risen fast at ... operating officer and president of operations.",Now Cypress and Whitacre ... in order to get Americans -- and people around ...
... Clinical Trials ... Session -, SAN ... today announced that data from an ongoing,Phase 1-2 clinical trial showed that ... prostate specific,antigen (PSA), a marker of tumor growth, in the lowest expanded ...
Cached Biology Technology:AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) 2Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 3
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2
... common condition that causes frequent nighttime trips to ... treatment that shrinks the prostate, suggests a study being ... Scientific Meeting in New Orleans. The early findings hail ... embolization (PAE), which reduces blood flow to the prostate, ...
... The largest genetic search for "obesity genes" in people of ... regions of the human genome that influence obesity in these ... Health and Information Sciences Department of Epidemiology and Population Health ... 2013), published their findings in Nature Genetics . ...
... a system of genes that bacteria use to defend themselves ... some bacteria evade the mammalian immune system. The results ... . CRISPR is itself a sort of immune system ... seeking to prevent phages, the viruses that infect bacteria, from ...
Cached Biology News:Nonsurgical treatment turns back the clock, shrinks enlarged prostate 2Genetic discovery found to influence obesity in people of African ancestry 2Bacterial security agents go rogue 2Bacterial security agents go rogue 3
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: